SOUTH SAN FRANCISCO – IDEAYA Biosciences () announced today the initiation of Part 2 monotherapy expansion in its Phase 1/2 clinical trial evaluating IDE892, a PRMT5 inhibitor, in MTAP-deleted solid tumors, focusing on non-small cell lung cancer and pancreatic ductal adenocarcinoma.
The company stated that the expansion was initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved. The maximum tolerated dose has not yet been reached in the ongoing dose escalation, according to the press release statement.
IDE892 demonstrates 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding. The drug has a CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the seven major cytochrome P450 enzymes.
“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
The company is conducting combination studies with IDE892 and IDE397, its MAT2A inhibitor, in MTAP-deleted NSCLC and PDAC. IDEAYA also entered into a clinical collaboration with Roche evaluating IDE892 in combination with RG6505, Roche’s pan-RAS inhibitor, in MTAP-deleted pancreatic ductal adenocarcinoma. The company targets first-patient-in for the IDE892 and pan-RAS combination in the second half of 2026.
MTAP deletion is estimated to occur in up to 40% of pancreatic ductal adenocarcinoma and approximately 15% of non-small cell lung cancer. There are currently no approved therapies for MTAP-deleted cancers.
IDEAYA is advancing a CDKN2A program through preclinical toxicology studies, targeting an investigational new drug application in the first half of 2027. The company plans to host a MTAP/CDKN2A, KRAS, and Pancreatic Cancer R&D Day in the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
